[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 56 of about 56
1. Khan AA, Davenport K: A reminder of the association between Clostridium septicum and colonic adenocarcinoma. Int Semin Surg Oncol; 2006;3:12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A reminder of the association between Clostridium septicum and colonic adenocarcinoma.
  • We present the case of a patient, with previously unknown liver metastases, presenting with a liver abscess and Clostridium septicum septicaemia. C. septicum is known to be associated with both malignancy and immunosuppression and therefore in patients where this organism is isolated, efforts must be made to exclude an occult underlying malignancy or haematological disorder.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anaerobe. 1995 Feb;1(1):11-6 [16887501.001]
  • [Cites] Arch Surg. 1991 May;126(5):642-5 [2021349.001]
  • [Cites] Medicine (Baltimore). 1989 Jan;68(1):30-7 [2642585.001]
  • [Cites] Cancer. 1986 May 15;57(10):2045-8 [3456820.001]
  • [Cites] Arch Surg. 1984 May;119(5):546-50 [6712467.001]
  • [Cites] Ann Surg. 1981 Mar;193(3):361-4 [7212798.001]
  • [Cites] Surgery. 1995 Oct;118(4):592-7; discussion 597-8 [7570310.001]
  • (PMID = 16646975.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1459865
  •  go-up   go-down


2. Bonatti H, Huguet K, McLaughlin S, Stockland A, Aranda-Michel J, Al Haddad M, Dougherty M, Fitzpatrick P, Kim G, Martin K, Hinder R, Nguyen JH: Whipple's procedure in a renal transplant recipient with polycystic liver disease. JOP; 2008;9(4):515-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whipple's procedure in a renal transplant recipient with polycystic liver disease.
  • CONTEXT: Polycystic disease is a rare disorder, which most commonly manifests in the kidney and liver.
  • CASE REPORT: We report a patient with polycystic liver and kidney disease who successfully underwent a Whipple's procedure for pancreatic adenocarcinoma.
  • CONCLUSION: Although technical difficulty may increase, pancreaticoduodenectomy can be safely performed in patients with polycystic liver disease.
  • [MeSH-major] Adenocarcinoma / surgery. Cysts / complications. Kidney Transplantation. Liver Diseases / complications. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy. Polycystic Kidney Diseases / complications


3. Lazzareschi I, Barone G, Mastrangelo S, Furfaro IF, Rando G, Riccardi R: Could APC gene screening be useful in children with hepatoblastoma? Early onset of adenocarcinoma in a child with familial adenomatous polyposis and hepatoblastoma. Tumori; 2009 Nov-Dec;95(6):819-22
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Could APC gene screening be useful in children with hepatoblastoma? Early onset of adenocarcinoma in a child with familial adenomatous polyposis and hepatoblastoma.
  • Familial adenomatous polyposis is an inherited disorder characterized by the development of hundreds of colorectal adenomas during adolescence, which in many cases will transform into colorectal cancer by the fourth decade of life, along with the development of various malignant tumors including hepatoblastoma.
  • We report on a female patient with a de novo interstitial deletion of 5q21.3-q23.3, encompassing the APC gene, associated with adenomatous polyposis and early colorectal cancer, hepatoblastoma, epidermoid cysts, mental retardation, several mild dysmorphic signs and lower limb venous thrombosis.
  • [MeSH-major] Adenocarcinoma / genetics. Adenomatous Polyposis Coli / genetics. Colonic Neoplasms / genetics. Gene Deletion. Genes, APC. Genetic Testing. Hepatoblastoma / genetics. Liver Neoplasms / genetics


Advertisement
4. Katabi N: Neoplasia of gallbladder and biliary epithelium. Arch Pathol Lab Med; 2010 Nov;134(11):1621-7
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Diagnosis of biliary neoplasia can be challenging but is essential for the appropriate clinical management of patients.
  • Therefore, it is important to recognize the morphologic features of the biliary neoplasms to report a correct diagnosis. OBJECTIVES:.
  • (1) To discuss the differential diagnosis of dysplasia in the gallbladder and differentiate dysplasia from reactive atypia and invasive carcinoma, (2) review the histologic features of adenoma and polypoid biliary lesions, (3) highlight the differential diagnosis of adenocarcinoma in liver biopsy, and (4) discuss the differential diagnosis of atypical biliary glandular lesions.
  • Careful examination of the histologic features of these lesions and familiarity with their morphology can help to achieve the correct diagnosis.
  • [MeSH-minor] Diagnosis, Differential. Humans. Metaplasia / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21043815.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


5. Cleary JM, Tanabe KT, Lauwers GY, Zhu AX: Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist; 2009 Nov;14(11):1095-105
Hazardous Substances Data Bank. CETUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver.
  • Colorectal cancer patients with isolated liver metastasis are potentially cured with surgical resection.
  • Recent advances in systemic chemotherapy have increased the ability to convert unresectable metastatic liver lesions to resectable lesions.
  • In this review, we summarize the current clinical experience with these hepatic toxicities and discuss the role they play in determining postoperative morbidity.
  • Finally, we give specific clinical examples of how multidisciplinary teams can best manage patients receiving preoperative chemotherapy for potentially resectable liver metastases.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / adverse effects. Colorectal Neoplasms / drug therapy. Drug-Induced Liver Injury / etiology. Liver Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19880627.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 2S9ZZM9Q9V / Bevacizumab; PQX0D8J21J / Cetuximab
  • [Number-of-references] 74
  •  go-up   go-down


6. VanSaun MN, Lee IK, Washington MK, Matrisian L, Gorden DL: High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. Am J Pathol; 2009 Jul;175(1):355-64
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model.
  • Non-alcoholic fatty liver disease (NAFLD), which includes steatosis and its progression to non-alcoholic steatohepatitis, is a liver disorder of increasing clinical significance.
  • Here we characterize a murine model of high fat diet-induced NAFLD with progression from liver steatosis to histological features compatible with steatohepatitis and more advanced stages of NAFLD in humans, including chronic portal inflammation, pericellular and bridging fibrosis, Mallory body formation, and bile ductular reaction.
  • Chronic changes induced by the prolonged consumption of a high-fat diet alone culminate in the development of primary liver dysplasias.
  • Importantly, we extend these studies to demonstrate that even the early stages of uncomplicated steatosis provide a permissive microenvironment for the growth of colon cancer cells that are metastatic to the liver.
  • High fat diet-induced steatosis, coupled with a splenic injection model of experimental liver metastasis using syngeneic MC38 colon cancer cells, resulted in an increased number of secondary tumor nodules and metastatic burden in steatotic livers.
  • These results suggest that the modulation of specific host factors in the steatotic liver contributes to tumor progression in the microenvironment of NAFLD.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2007 Sep;42(9):1023-30 [17710666.001]
  • [Cites] Nutr Rev. 2007 Jun;65(6 Pt 2):S57-63 [17605315.001]
  • [Cites] Curr Opin Lipidol. 2008 Feb;19(1):25-9 [18196983.001]
  • [Cites] Clin Sci (Lond). 2008 Apr;114(7):457-66 [18302533.001]
  • [Cites] Curr Drug Targets. 2008 May;9(5):375-80 [18473765.001]
  • [Cites] Breast Cancer Res Treat. 2008 Sep;111(2):329-42 [17939036.001]
  • [Cites] Cancer Lett. 2008 Aug 28;267(2):204-15 [18448242.001]
  • [Cites] Cytokine. 2008 Sep;43(3):374-9 [18701317.001]
  • [Cites] Arch Pathol Lab Med. 2008 Nov;132(11):1761-6 [18976012.001]
  • [Cites] Histochem Cell Biol. 2008 Dec;130(6):1079-90 [18953558.001]
  • [Cites] Digestion. 2009;79 Suppl 1:26-32 [19153487.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):163-76 [10652271.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Semin Liver Dis. 2001;21(1):89-104 [11296700.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5016-23 [11431335.001]
  • [Cites] Eur J Immunol. 2001 Jul;31(7):1981-8 [11449350.001]
  • [Cites] Jpn J Cancer Res. 2002 Feb;93(2):125-32 [11856475.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2002 Oct;16(5):679-90 [12406439.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):1-10 [12925950.001]
  • [Cites] Med Electron Microsc. 2004 Jun;37(2):114-8 [15221653.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):60-6 [15246209.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S97-103 [15508109.001]
  • [Cites] Cancer Res. 1980 Jul;40(7):2083-128 [7388781.001]
  • [Cites] Lab Invest. 1988 Dec;59(6):848-56 [2462130.001]
  • [Cites] Am J Pathol. 1989 Mar;134(3):505-13 [2466401.001]
  • [Cites] Biochem J. 1997 Mar 15;322 ( Pt 3):809-14 [9148753.001]
  • [Cites] Liver Int. 2005 Apr;25(2):294-304 [15780053.001]
  • [Cites] J Leukoc Biol. 2005 Apr;77(4):552-9 [15629884.001]
  • [Cites] Obes Surg. 2005 Mar;15(3):442-6 [15826485.001]
  • [Cites] Diabetologia. 2005 Apr;48(4):634-42 [15747110.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2005 May;4(2):173-7 [15908310.001]
  • [Cites] Diabet Med. 2005 Sep;22(9):1129-33 [16108837.001]
  • [Cites] Front Biosci. 2006;11:479-91 [16146745.001]
  • [Cites] Eur Rev Med Pharmacol Sci. 2005 Sep-Oct;9(5):291-3 [16231592.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112 [16447287.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1079-86 [17164441.001]
  • [Cites] Int J Cancer. 2007 Aug 1;121(3):495-500 [17417772.001]
  • [Cites] Clin Liver Dis. 2007 Feb;11(1):17-23, vii [17544969.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):830-9 [17211838.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):556-64 [17459514.001]
  • (PMID = 19541928.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50CA095103; United States / NCI NIH HHS / CA / P50 CA095103; United States / NIDDK NIH HHS / DK / P30 DK058404; United States / NCI NIH HHS / CA / R01CA060867; United States / NIDDK NIH HHS / DK / K08 DK70708-01; United States / NIDDK NIH HHS / DK / P30DK058404; United States / NIDDK NIH HHS / DK / K08 DK070708; United States / NCI NIH HHS / CA / R01 CA060867
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats
  • [Other-IDs] NLM/ PMC2708821
  •  go-up   go-down


7. Sakai M, Oguri T, Sato S, Hattori N, Bessho Y, Achiwa H, Maeda H, Niimi T, Ueda R: Spontaneous hepatic rupture due to metastatic tumor of lung adenocarcinoma. Intern Med; 2005 Jan;44(1):50-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous hepatic rupture due to metastatic tumor of lung adenocarcinoma.
  • A 64-year-old man diagnosed as lung adenocarcinoma with hepatic tumor was admitted to our hospital.
  • He carried the hepatitis B virus but was negative for PIVKA-II and alpha-fetoprotein, and hence we diagnosed a case of stage IV lung adenocarcinoma.
  • We diagnosed hemorrhagic ascites due to spontaneous rupture of the liver tumor.
  • Hemorrhagic ascites due to metastatic liver tumor is rare and the sudden onset of abdominal symptoms is an indicator of rupture.
  • [MeSH-major] Adenocarcinoma / secondary. Liver Diseases / etiology. Liver Neoplasms / complications. Liver Neoplasms / secondary. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15704663.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Klopfleisch R, van der Grinten E, Gruber AD: Metastatic uterine adenocarcinoma and hepatic lipomatosis in a llama (Lama glama). J Vet Diagn Invest; 2009 Mar;21(2):280-2
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic uterine adenocarcinoma and hepatic lipomatosis in a llama (Lama glama).
  • Postmortem examination revealed an infiltrative uterine adenocarcinoma with widespread metastases.
  • The neoplasm completely replaced and infiltrated the myometrium of the uterine body and cervix and metastasized largely to the serosal surfaces of the peritoneal cavity.
  • [MeSH-major] Adenocarcinoma / veterinary. Camelids, New World. Lipomatosis / veterinary. Papillomaviridae / isolation & purification. Papillomavirus Infections / veterinary. Uterine Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19286516.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Viral Proteins
  •  go-up   go-down


9. Hucl T, Kylanpää-Bäck ML, Witt H, Künzli B, Lempinen M, Schneider A, Kemppainen E, Löhr M, Friess H, Ockenga J, Rosendahl J, Schulz HU, Gress T, Singer MV, Pfützer RH: HFE genotypes in patients with chronic pancreatitis and pancreatic adenocarcinoma. Genet Med; 2007 Jul;9(7):479-83
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HFE genotypes in patients with chronic pancreatitis and pancreatic adenocarcinoma.
  • PURPOSE: The homozygous p.C282Y variant of the HFE gene is a major risk factor for hereditary hemochromatosis, a disorder of iron metabolism resulting in progressive iron accumulation in a variety of organs including the pancreas.
  • Heterozygosity of p.C282Y and p.H63D may increase susceptibility to chronic liver and pancreatic disease.
  • This study determines the frequencies of p.C282Y and p.H63D alterations in patients with chronic pancreatitis and pancreatic adenocarcinoma.
  • METHODS: In total, 958 patients (349 with alcoholic pancreatitis, 343 with idiopathic pancreatitis, 64 with familial chronic pancreatitis, 34 with acute pancreatitis, and 168 with pancreatic adenocarcinoma) were enrolled and compared with 681 healthy and 100 alcoholic controls.
  • RESULTS: No significant differences were found in heterozygosity for p.C282Y and p.H63D when patients with alcoholic (8.0/21.5%), idiopathic (7.3/24.5%), or familial (9.8/23.0%) pancreatitis, or pancreatic adenocarcinoma (5.4/28.6%) were compared with healthy (6.2/24.8%) and alcoholic (7.0/25.0%) controls.
  • CONCLUSION: Although hemochromatosis is associated with pancreatic pathology, the p.C282Y and p.H63D variants do not play a significant role in the pathogenesis of chronic pancreatitis or pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Histocompatibility Antigens Class I / genetics. Membrane Proteins / genetics. Pancreatic Neoplasms / genetics. Pancreatitis, Chronic / genetics. Polymorphism, Restriction Fragment Length

  • Genetic Alliance. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17666895.001).
  • [ISSN] 1098-3600
  • [Journal-full-title] Genetics in medicine : official journal of the American College of Medical Genetics
  • [ISO-abbreviation] Genet. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HFE protein, human; 0 / Histocompatibility Antigens Class I; 0 / Membrane Proteins
  •  go-up   go-down


10. Dechaphunkul A, Kanngurn S, Dechsukhum C, Tanutit P, Khow-Ean U, Sunpaweravong P: The significance of galectin-3 immunohistochemistry, clinical characteristics and liver imaging in differentiating intrahepatic cholangiocarcinoma from adenocarcinoma liver metastasis. J Med Assoc Thai; 2010 May;93(5):523-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of galectin-3 immunohistochemistry, clinical characteristics and liver imaging in differentiating intrahepatic cholangiocarcinoma from adenocarcinoma liver metastasis.
  • OBJECTIVE: To identify differences of Galectin-3 (Gal-3) immunostaining, clinical profiles, and images in patients with intrahepatic cholangiocarcinoma (IHC) and adenocarcinoma liver metastasis, and be able to recognize these parameters as diagnostic tools for differentiating these two diseases.
  • MATERIAL AND METHOD: Histological slides from patients with IHC and adenocarcinoma liver metastasis were reviewed Immunohistochemical staining for Gal-3, Cytokeratin-7 (CK-7), and Cytokeratin-20 (CK-20) was performed and the results categorized.
  • Moreover clinical characteristics and liver images of the patients were reviewed.
  • RESULTS: Eighty-two patients were evaluated, 31 IHC and 51 adenocarcinoma liver metastasis.
  • Finding showed that 86% of them were IHC whereas only 14% were in adenocarcinoma liver metastasis.
  • All patients with liver images showing a single lesion, located at central site, and having intrahepatic duct dilatation were IHC.
  • On the other hand, 77% of patients with liver imaging showing multiple liver masses, located at peripheral site and having no intrahepatic duct dilatation were adenocarcinoma liver metastasis while only 23% were in IHC.
  • CONCLUSION: Adding Gal-3 to CK-7 and CK-20 immunohistochemistry has benefits to differentiate IHC from adenocarcinoma liver metastasis.
  • Furthermore, liver imaging profiles also give benefits for differentiating between these two diseases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Bile Duct Neoplasms / diagnosis. Cholangiocarcinoma / diagnosis. Galectin 3 / metabolism. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Bile Ducts, Intrahepatic / metabolism. Bile Ducts, Intrahepatic / pathology. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Keratin-20 / metabolism. Keratin-7 / metabolism. Liver / radiography. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524437.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


11. Halama J, Neoral C, Klos D: [Unusual approach to a liver metastasis resection]. Rozhl Chir; 2010 Sep;89(9):461-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual approach to a liver metastasis resection].
  • [Transliterated title] Neobvyklý prístup k resekci metastázy jater.
  • Metastatic disorder is a common finding in patients with abdominal tumors.
  • This case review presents a case of a 52-year old female with a forth relapse of her liver metastasis in the liver segment VIII.
  • In the current procedure, the authors opted for a thoracic transdiaphragmatic approach, which provided perfect view of the site in order to remove the metastasis in the liver segment VIII with partial excision of the adjacent diaphragm.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Hepatectomy / methods. Liver Neoplasms / secondary. Liver Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21121157.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


12. Eickhoff A, Spiethoff A, Hartmann D, Jakobs R, Weickert U, Schilling D, Eickhoff JC, Bohrer MH, Riemann JF: [Space-occupying lesions in the liver: incidence of adenocarcinoma metastases of unknown primary site]. Dtsch Med Wochenschr; 2007 Feb 23;132(8):369-74
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Space-occupying lesions in the liver: incidence of adenocarcinoma metastases of unknown primary site].
  • [Transliterated title] Unklare hepatische Raumforderungen: Häufigkeit von Adenokarzinom-Metastasen eines unbekannten Primärtumors.
  • BACKGROUND AND OBJECTIVE: The diagnostic approach to newly detected space-occupying lesions in the liver can be difficult and a histogenetic classification of the primary tumor is impossible in some cases.
  • The incidence of this diagnosis depends on the clinical and histochemical methods used.
  • It was the main aim of this study to analyze the true incidence of adenocarcinoma metastases of the liver with an unknown primary cancer after application of a standardized protocol of clinical and immunhistochemical diagnostic tests and a long-term follow-up.
  • PATIENTS AND METHODS: Between January 2000 and January 2003 127 consecutive patients underwent diagnostic ultrasound-guided biopsy of a space-occupying lesion in the liver.
  • Primary tumors of the liver were found in 21 cases and non-hepatocellular tumors (metastases) were documented in 106 patients, 82 of the latter (77%) had metastases of an adenocarcinoma.
  • The further diagnostic approach was based on histochemistry, immunhistochemistry and imaging techniques, making possible a full diagnosis of primary tumor in a further 59 (72%) cases.
  • Thus the incidence of an adenocarcinoma of the liver of unknown primary site was 23 of 127 cases (18%).
  • CONCLUSIONS: Although there is a wide variety of modern diagnostic methods today, the histogenetic classification of hepatic metastases is not always possible.
  • [MeSH-major] Adenocarcinoma / secondary. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Incidence. Karnofsky Performance Status. Liver / pathology. Liver / ultrasonography. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17299675.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Goldstein NS, Bosler D: An approach to interpreting immunohistochemical stains of adenocarcinoma in small needle core biopsy specimens: the impact of limited specimen size. Am J Clin Pathol; 2007 Feb;127(2):273-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An approach to interpreting immunohistochemical stains of adenocarcinoma in small needle core biopsy specimens: the impact of limited specimen size.
  • Interpreting immunohistochemical stains of metastatic adenocarcinoma in small needle core biopsy specimens is not always straightforward.
  • We studied the effects of small specimen size on immunohistochemical stain results in 20 colorectal adenocarcinoma hepatic resection specimens stained with cytokeratin (CK)7 and CK20.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle / methods. Colorectal Neoplasms / pathology. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Biospecimen Research Database. Biospecimen Research Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17210515.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


14. Szumiło J, Swatek J, Chrościcki A, Dudka J, Korobowicz E: Colonic adenocarcinoma with numerous paneth and endocrine cells. Pol J Pathol; 2005;56(2):89-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic adenocarcinoma with numerous paneth and endocrine cells.
  • Numerous granular eosinophilic cells corresponding to Paneth cells were unexpectedly revealed in a moderately differentiated adenocarcinoma of the hepatic flexure of the colon in a 76-year-old man.
  • The light microscopic and ultrastructural features of this rare neoplasm are described together with detailed clinical data.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Paneth Cells / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16092671.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins
  •  go-up   go-down


15. Ghittoni G, Caturelli E, Viera FT: Intrabile duct metastasis from colonic adenocarcinoma without liver parenchyma involvement: contrast enhanced ultrasonography detection. Abdom Imaging; 2010 Jun;35(3):346-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrabile duct metastasis from colonic adenocarcinoma without liver parenchyma involvement: contrast enhanced ultrasonography detection.
  • It is well-known that biliary duct invasion with intraluminal growth is one of the developmental patterns of primary liver tumors, and macroscopic intrabiliary growth of liver metastases in colorectal cancer is found with high frequency.
  • We describe the first recorded case of a metastasis from colorectal cancer involving solely the common hepatic biliary duct, without invasion of contiguous liver parenchyma.
  • A correct diagnosis was obtained by means of contrast enhanced ultrasound and ultrasound-guided fine needle aspiration biopsy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Hepatic Duct, Common / pathology. Ultrasonography, Doppler, Color
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Cholangiography. Common Bile Duct / pathology. Common Bile Duct / ultrasonography. Humans. Image Enhancement. Lymphatic Metastasis. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19294464.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Wang L, Vuolo M, Suhrland MJ, Schlesinger K: HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates. Acta Cytol; 2006 May-Jun;50(3):257-62
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates.
  • OBJECTIVE: To investigate immunohistochemical staining of hepatocyte paraffin-1 (HepPar1), alpha-fetoprotein (AFP), polyclonal carcinoembryonic antigen (pCEA), monoclonal CEA (mCEA), MOC-31 and CD10 for differential diagnosis of hepatocellular carcinoma (HCC) from metastatic adenocarcinoma (MA) on fine needle aspiration biopsy (FNAB).
  • We suggest using HepPar1, pCEA, CD10, MOC-31 and mCEA as a panel for distinguishing HCC from MA in liver FNAB.
  • [MeSH-major] Adenocarcinoma / secondary. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / pathology. Liver / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Biopsy, Fine-Needle. Carcinoembryonic Antigen / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Neprilysin / analysis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780018.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


17. Vrettou E, Hytiroglou P, Sikas N, Soultoyannis I, Goodman ZD: Hepatic adenocarcinoma expressing inhibin in a young patient on oral contraceptives. Virchows Arch; 2005 May;446(5):560-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic adenocarcinoma expressing inhibin in a young patient on oral contraceptives.
  • A case of primary hepatic carcinoma is reported, which occurred in a 24-year-old woman with a 10-year history of oral contraceptive use, and demonstrated unique morphologic and immunohistochemical features.
  • The tumor was located in the left hepatic lobe, measured 14 cm at its widest, and showed histologic heterogeneity.
  • Interestingly, they were positive for inhibin, a protein that is known to be expressed in sex cord-stromal tumors of the ovary, trophoblastic neoplasms and adrenal cortical tumors, but not in hepatic tumors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Contraceptives, Oral, Combined / administration & dosage. Inhibins / analysis. Liver Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1998 Jul;11(7):656-64 [9688187.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2112-6 [3567872.001]
  • [Cites] Mod Pathol. 1998 Jun;11(6):516-24 [9647588.001]
  • [Cites] Int J Gynecol Pathol. 1999 Apr;18(2):144-50 [10202672.001]
  • [Cites] Mod Pathol. 1998 Dec;11(12):1160-4 [9872645.001]
  • [Cites] Am J Clin Pathol. 1999 Feb;111(2):229-34 [9930145.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):591-7 [12808065.001]
  • [Cites] Hum Pathol. 2002 Dec;33(12):1175-81 [12514785.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1387-93 [11391527.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):2051-5 [1717133.001]
  • (PMID = 15815932.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Contraceptives, Oral, Combined; 0 / KRT7 protein, human; 0 / Keratin-7; 57285-09-3 / Inhibins; 68238-35-7 / Keratins
  •  go-up   go-down


18. Eigenbrod T, Kullmann F, Klebl F: Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report. Int J Gastrointest Cancer; 2006;37(2-3):94-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report.
  • Small bowel adenocarcinoma (SBA) is a very rare tumor entity but occurs in up to 5% of patients suffering from familiar adenomatous polyposis (FAP).
  • Because of nonspecific symptoms, diagnosis is usually made with delay, which contributes to high rates of metastatic disease at the time of diagnosis.
  • In October 2001, a 51-year-old woman with attenuated FAP, that had total proctocolectomy in 1994 was diagnosed with a jejunal adenocarcinoma.
  • Because a computed tomography (CT) scan in April 2002 revealed multiple liver metastases, chemotherapy with nine cycles FOLFOX6 was initiated.
  • This solitary residual liver metastasis was resected in January 2004.
  • To date, more than 3 years after liver resection, the patient is still in complete remission and undergoes regular restaging investigations.
  • Resection of liver metastases from SBA combined with neoadjuvant and adjuvant chemotherapy can result in extended disease-free survival and should undergo further investigation.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hepatectomy. Ileal Neoplasms / therapy. Jejunal Neoplasms / therapy. Liver Neoplasms / therapy. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] ANZ J Surg. 2001 Jul;71(7):428-37 [11450920.001]
  • [Cites] Br J Cancer. 1998 Aug;78(4):508-10 [9716035.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):66-71 [6691554.001]
  • [Cites] J Clin Gastroenterol. 2001 Oct;33(4):267-82 [11588539.001]
  • [Cites] Surg Today. 1997;27(1):60-3 [9035302.001]
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] Isr Med Assoc J. 2003 Mar;5(3):188-92 [12725140.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3761-9 [12963697.001]
  • [Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]
  • [Cites] Chirurg. 1999 May;70(5):571-7 [10412601.001]
  • [Cites] Oncologist. 2005 Feb;10(2):132-7 [15709215.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Oncology (Williston Park). 2002 Oct;16(10):1364-9; discussion 1370, 1372-3 [12435206.001]
  • [Cites] Ann Oncol. 2009 Apr;20(4):674-80 [19179549.001]
  • [Cites] Z Gastroenterol. 2004 Oct;42(10 ):1129-77 [15508058.001]
  • (PMID = 17827529.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0H43101T0J / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


19. Sato Y, Takayama T, Nikaido T, Wada Y, Sagawa T, Abe S, Sato T, Iyama S, Murase K, Araki H, Sato Y, Kato J, Niitsu Y, Chiba H: Report of an autopsy case of colon cancer with amyotrophic lateral sclerosis. Nihon Shokakibyo Gakkai Zasshi; 2007 Sep;104(9):1365-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Amyotrophic lateral sclerosis (ALS) is a degenerative disease involving both upper and lower motor neurons and the pathogenesis of this disorder is still unknown.
  • A 60-year-old man with rectal cancer (Stage IV) having multiple lung, liver and para-aortic lymph node metastases underwent anterior resection of the rectum as palliative surgery.
  • Lung and lymph node metastases decreased after 2 courses of chemotherapy using CPT-11 and 5-FU/LV but liver metastases were enlarged, following up increase in CEA.
  • [MeSH-major] Adenocarcinoma / secondary. Amyotrophic Lateral Sclerosis / etiology. Colonic Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged

  • Genetic Alliance. consumer health - Amyotrophic Lateral Sclerosis.
  • MedlinePlus Health Information. consumer health - Amyotrophic Lateral Sclerosis.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17827908.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


20. Kuroki T, Fukuda K, Tajima Y, Matsuzaki S, Kitajima T, Furui J, Kanematsu T: Parapapillary choledochoduodenal fistula associated with cholangiocarcinoma. J Hepatobiliary Pancreat Surg; 2005;12(2):143-6
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parapapillary choledochoduodenal fistula is a rare disorder.
  • A 61-year-old woman was admitted to our hospital for further examination of a liver tumor.
  • She had no clinical symptoms, but computed tomography scans showed an irregularly contoured liver tumor which was histologically confirmed to be adenocarcinoma, by a needle biopsy examination.
  • [MeSH-minor] Adenocarcinoma / etiology. Ampulla of Vater. Amylases / analysis. Bile / microbiology. Female. Helicobacter pylori / isolation & purification. Humans. Middle Aged. Risk Factors

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868079.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 3.2.1.- / Amylases
  •  go-up   go-down


21. Gandhi K, Parikh P, Aronow WS, Desai H, Amin H, Sharma M, Rubinstein A: A case of explosive progression of hepatocellular carcinoma in a patient with common variable immunodeficiency (CVID). J Gastrointest Cancer; 2010 Dec;41(4):281-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: While it is well known that patients with common variable immunodeficiency (CVID) are predisposed to various malignancies, primarily non-Hodgkin's lymphoma and gastric carcinomas, to our knowledge no cases of hepatocellular carcinoma have been reported in the absence of preexisting liver disease.
  • The patient was on prophylactic intravenous gammaglobulin and had received several years earlier a course of rituximab for an autoimmune disorder.
  • CONCLUSIONS: Although patients with CVID are predisposed to malignancies such as lymphoma and adenocarcinoma of the stomach, rapidly progressive hepatocellular carcinoma in the absence of any preexisting liver disease has not been described.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Common Variable Immunodeficiency / complications. Liver Neoplasms / etiology

  • Genetic Alliance. consumer health - Common Variable Immunodeficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Arch Allergy Immunol. 2009;150(4):311-24 [19571563.001]
  • [Cites] J Clin Immunol. 2007 May;27(3):308-16 [17510807.001]
  • [Cites] Clin Exp Med. 2004 Apr;3(4):211-7 [15103511.001]
  • [Cites] J Intern Med. 1996 Aug;240(2):99-102 [8810936.001]
  • [Cites] Hepatol Res. 2008 Apr;38(4):415-20 [18021227.001]
  • [Cites] Clin Immunol. 1999 Dec;93(3):190-7 [10600329.001]
  • [Cites] Clin Immunol. 1999 Jul;92(1):34-48 [10413651.001]
  • [Cites] Q J Med. 1993 Jan;86(1):31-42 [8438047.001]
  • [Cites] Ann Allergy Asthma Immunol. 2005 May;94(5 Suppl 1):S1-63 [15945566.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):489-502 [18692715.001]
  • [Cites] Eur J Pediatr. 1996 Jul;155(7):532-4 [8831072.001]
  • [Cites] Curr Opin Genet Dev. 2007 Jun;17(3):201-12 [17467261.001]
  • [Cites] Lancet. 1985 Feb 2;1(8423):263-6 [2857327.001]
  • [Cites] Clin Exp Immunol. 2002 Dec;130(3):495-500 [12452841.001]
  • [Cites] Am J Hematol. 2002 Mar;69(3):171-8 [11891803.001]
  • [Cites] J Clin Immunol. 1987 Jul;7(4):294-9 [3611296.001]
  • (PMID = 20473587.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunologic Factors
  •  go-up   go-down


22. Hussain T, Salamat A, Farooq MA, Hassan F, Hafeez M: Indications for endoscopic ultrasound and diagnosis on fine-needle aspiration and cytology. J Coll Physicians Surg Pak; 2009 Apr;19(4):223-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indications for endoscopic ultrasound and diagnosis on fine-needle aspiration and cytology.
  • OBJECTIVE: To determine common indications for requesting Endoscopic Ultrasound (EUS) and to describe the diagnosis made after endoscopic ultrasound/Fine-Needle Aspiration and Cytology (FNAC) during two years at a tertiary gastrointestinal unit.
  • An on-site cytopathologist made the provisional cytopathological diagnosis.
  • Major indications for referral were lymphadenopathy in 92 (49%), suspected growth pancreas in 57 (28%), growth of stomach in 20 (11%) and a heterogeneous group included esophageal, liver, retroperitoneal masses, rectal and other pathologies.
  • Final diagnosis out of 67 FNAC/histopathology of lymph nodes were tuberculosis in 26 and malignant lesions in 23.
  • These included metastatic adenocarcinoma in 8, lymphoproliferative disorder in 7, metastatic squamous cell carcinoma in 5, small cell carcinoma in 2 and anaplastic in 1.
  • Pancreatic tumours were adenocarcinoma in 16, poorly differentiated in 3 and neuroendocrine in 2.
  • Stomach tumours were found in 11, and included lymphomas 5, GIST 3, carcinoids 2, metastatic choriocarcinoma 1 and adenocarcinoma in 1.
  • Pancreatic adenocarcinoma was another common cause for asking EUS.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endosonography / methods. Lymphatic Diseases / diagnosis. Pancreatic Neoplasms / diagnosis. Stomach Neoplasms / diagnosis. Tuberculosis, Lymph Node / diagnosis
  • [MeSH-minor] Abdomen. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle / methods. Cross-Sectional Studies. Diagnosis, Differential. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Lymphatic Metastasis / ultrasonography. Male. Mediastinum. Middle Aged. Neoplasm Staging. Pancreatitis, Chronic / diagnosis. Pancreatitis, Chronic / pathology. Pancreatitis, Chronic / ultrasonography. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19356336.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


23. Zhanaeva SY, Korolenko TA, Nekrasov BG, Nikolin VP, Kaledin VI: Stimulation of macrophages increases, while suppression of these cells inhibits metastatic dissemination of two transplantable mouse tumors in the liver and lungs. Bull Exp Biol Med; 2005 Oct;140(4):449-51
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stimulation of macrophages increases, while suppression of these cells inhibits metastatic dissemination of two transplantable mouse tumors in the liver and lungs.
  • Stimulation of mouse tissue macrophages with carboxymethylated beta-(1-->43)-D-glycan 1 day before intravenous injection of tumor cells increased the number and weight of implants (experimental metastases) of mouse hepatocarcinoma and adenocarcinoma in the liver and lungs, respectively.
  • Suppression of liver macrophages with gadolinium chloride or sequestration of cells during intraperitoneal administration of macrophage attractants inhibited metastatic dissemination of hepatocarcinoma and adenocarcinoma in the liver and lungs, respectively.
  • [MeSH-major] Adenocarcinoma / secretion. Carcinoma, Hepatocellular / secretion. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Macrophages / immunology
  • [MeSH-minor] Animals. Gadolinium / pharmacology. Male. Mice. Mice, Inbred Strains. Neoplasm Transplantation. Polysaccharides / pharmacology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16671578.001).
  • [ISSN] 0007-4888
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Polysaccharides; AU0V1LM3JT / Gadolinium; P7082WY76D / gadolinium chloride
  •  go-up   go-down


24. Rohart C, Badelon I, Fajnkuchen F, Nghiem-Buffet S, Chaine G: [Ophthalmologic disease in sarcoid-like granulomatosis and true sarcoidosis in immunodeficiency. Four case reports]. J Fr Ophtalmol; 2008 Sep;31(7):683-91
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Atteintes ophtalmologiques de la sarcoïdose et des "sarcoid-like reaction" dans les déficits immunitaires. A propos de 4 cas.
  • Granulomatosis lesions occurring after diagnosis of primary or secondary immunodeficiency are not accidental and have been described in a small number of patients suffering from various diseases: common variable immunodeficiency (CVID), malignancy (lymphoma and solid tumors), and acquired immunodeficiency syndrome (AIDS).
  • We report four patients, two with CVID and two with malignancy, in whom clinical granulomatosis appeared a few months to a few years after diagnosis of immunodeficiency.
  • They developed noncaseating granulomas of the lung, spleen and liver associated with conjunctival granulomas and bilateral panuveitis.
  • The granulomatous disorder was diagnosed after immunodeficiency on histopathological studies revealing noncaseating granulomas.
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Adult. Agammaglobulinemia / complications. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / therapy. Diagnosis, Differential. Female. Granuloma, Giant Cell / diagnosis. Granuloma, Giant Cell / etiology. Granuloma, Giant Cell / immunology. Humans. Liver Diseases / etiology. Liver Diseases / immunology. Lung Diseases / etiology. Lung Diseases / immunology. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Lymphatic Metastasis. Male. Middle Aged. Papilledema / etiology. Splenic Diseases / etiology. Splenic Diseases / immunology. Uterine Neoplasms / therapy

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18971853.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


25. G M, Tiwari SK, Sharma V, Habeeb MA, Khan AA, Cm H: Association of Helicobacter pylori restriction endonuclease-replacing gene, hrgA with overt gastrointestinal diseases. Arq Gastroenterol; 2008 Jul-Sep;45(3):225-9
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Helicobacter pylori has been proven to be responsible for causing various gastrointestinal disorders including gastric adenocarcinoma.
  • METHODS: Fifty-six indigenous strains of H. pylori from subjects with various gastric disorder were screened to assess the status of hrgA gene along with the cagA gene using simple polymerase chain reaction using specific oligonucleotide primers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18852951.001).
  • [ISSN] 1678-4219
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / Biomarkers; 0 / DNA, Bacterial; 0 / cagA protein, Helicobacter pylori; EC 3.1.21.4 / Deoxyribonucleases, Type II Site-Specific; EC 3.1.21.4 / HrgA protein, Helicobacter pylori
  •  go-up   go-down


26. Kaira K, Tsuchiya S, Sunaga N, Yanagitani N, Watanabe S, Imai H, Hisada T, Ishizuka T, Saito R, Mori M: A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer. Am J Clin Oncol; 2007 Feb;30(1):51-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB and IV NSCLC, >70 years of age, performance status (ECOG) 0-2, with adequate bone marrow, renal, liver and cardiac function, were treated with docetaxel and carboplatin.
  • Nonhematologic toxicities were generally mild, and included grade 3 constipation in 1 patient (4%) and grade 3 renal disorder in 1 patient (4%).
  • [MeSH-minor] Adenocarcinoma / drug therapy. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Neoplasm Staging. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278895.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


27. Lin CW, Hsu CC, Chang HC, Sun YC, Sun PL, Hsu CY, Perng DS: Hepatoid adenocarcinoma of the stomach with liver metastasis mimicking hepatocellular carcinoma: a case report. Cases J; 2009;2:6317

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid adenocarcinoma of the stomach with liver metastasis mimicking hepatocellular carcinoma: a case report.
  • INTRODUCTION: Hepatoid adenocarcinoma is a special type of extrahepatic alpha-fetoprotein-producing adenocarcinoma, which has a morphologic similarity to hepatocellular carcinoma.
  • We report a patient with underlying hepatitis B virus infection and hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma.
  • CASE PRESENTATION: We present the case of a 56-year-old Chinese female with underlying hepatitis B virus infection, who was found to have multiple hepatic tumors by abdominal ultrasound and an elevated level of serum alpha-fetoprotein.
  • However, the tumor histology of the stomach and liver revealed glandular adenocarcinoma with hepatoid foci.
  • The final diagnosis is hepatoid adenocarcinoma of the stomach with liver metastasis.
  • CONCLUSION: Hepatoid adenocarcinoma is an aggressive tumor with liver metastasis being the first clinical manifestation of the neoplasm.
  • Hepatoid adenocarcinoma of the stomach with liver metastasis should be considered in older patients with elevated serum alpha-fetoprotein and multiple hepatic tumors with underlying chronic liver disease.
  • An upper gastrointestinal endoscopy should be performed to exclude the possibility of hepatoid adenocarcinoma originating from the stomach to avoid potential misdiagnosis and inappropriate therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1985 Aug 15;56(4):840-8 [2410093.001]
  • [Cites] Presse Med. 1970 Jun 6;78(28):1277-8 [5426134.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2165-73 [6091861.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1827-35 [7689918.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1050-4 [7692729.001]
  • [Cites] Histopathology. 1997 Jul;31(1):47-54 [9253624.001]
  • [Cites] Mayo Clin Proc. 1997 Dec;72(12):1154-60 [9413299.001]
  • [Cites] Hepatology. 2000 Aug;32(2):200-4 [10915724.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):689-94 [11345832.001]
  • [Cites] Gastric Cancer. 2001;4(1):43-52 [11706627.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):137-44 [12591966.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1302-12 [14508391.001]
  • [Cites] Pathology. 2005 Jun;37(3):211-5 [16175893.001]
  • [Cites] Acta Gastroenterol Belg. 2006 Jul-Sep;69(3):330-7 [17168134.001]
  • [Cites] J Dig Dis. 2007 Feb;8(1):23-8 [17261131.001]
  • (PMID = 19918575.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769285
  •  go-up   go-down


28. Sarin S, Bernath A: Turcot syndrome (glioma polyposis): a case report. South Med J; 2008 Dec;101(12):1273-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Turcot's syndrome (glioma-polyposis) is a rare hereditary disorder characterized by association of colonic polyposis with primary tumors of the central nervous system.
  • [MeSH-major] Adenocarcinoma / pathology. Adenomatous Polyposis Coli / pathology. Cerebellar Neoplasms / pathology. Colonic Neoplasms / pathology. Medulloblastoma / pathology. Neoplastic Syndromes, Hereditary / pathology
  • [MeSH-minor] Adult. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / pathology. Diagnosis, Differential. Genetic Testing. Humans. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Male. Multiple Organ Failure / genetics. Multiple Organ Failure / pathology

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Turcot syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19005436.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Skrzycki M, Scibior-Bentkowska D, Podsiad M, Czeczot H: [Protein level of transcription factors AP-1 and NF-kappaB in selected human gastrointestinal tract tumors]. Pol Merkur Lekarski; 2008 Dec;25(150):510-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Materials were obtained from patients with alimentary tract tumors (stomach, liver; colon), diagnosed by routine histopathological examination.
  • RESULTS: In all examined alimentary tract tumors (gastric adenocarcinoma, hepatocellular carcinoma, colorectal adenocarcinoma and liver metastases) we observed changes in AP-1 and NF-kappaB protein level comparing with normal tissues.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205384.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NF-kappa B; 0 / Transcription Factor AP-1
  •  go-up   go-down


30. Yamashita Y, Taketomi A, Morita K, Fukuhara T, Ueda S, Sanefuji K, Iguchi T, Kayashima H, Sugimachi K, Maehara Y: The impact of surgical treatment and poor prognostic factors for patients with intrahepatic cholangiocarcinoma: retrospective analysis of 60 patients. Anticancer Res; 2008 Jul-Aug;28(4C):2353-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is a primary adenocarcinoma of the liver arising from the intrahepatic bile duct.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Cholangiocarcinoma / surgery. Liver Neoplasms / surgery

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751418.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


31. Sawant AD, Miller EL, Duignan DB, Brodfuehrer J, Winter SM, Nelson FR, Kamel A, Obach RS, Vaz AD: Understanding the clinical pharmacokinetics of a GABAA partial agonist by application of in vitro tools. Xenobiotica; 2010 Jul;40(7):476-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1. 4-Oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid (4-methylaminomethyl-phenyl)-amide (1), developed for general anxiety disorder, was discontinued from clinical development due to unsuitable oral pharmacokinetics.
  • Finally, in human epithelial colon adenocarcinoma cell line (Caco-2) and Madin-Darby canine kidney cells transwell flux experiments, (1) was shown to have relatively low permeability and a basolateral-to-apical flux ratio consistent with the activity of P-glycoprotein.
  • 5. In combination, a compounding of the contributions of MAO-A, hepatic uptake and efflux transporters, and P-glycoprotein to the disposition of (1) may underlie the low oral exposure, saturable clearance, and aberrant concentration versus time profiles observed for this compound in humans.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cells, Cultured. Cytochrome P-450 Enzyme System / metabolism. Dogs. Dose-Response Relationship, Drug. Humans. In Vitro Techniques. Liver / metabolism. Molecular Structure. Monoamine Oxidase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429841.001).
  • [ISSN] 1366-5928
  • [Journal-full-title] Xenobiotica; the fate of foreign compounds in biological systems
  • [ISO-abbreviation] Xenobiotica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid (4-methylaminomethylphenyl)amide; 0 / Anilides; 0 / Anti-Anxiety Agents; 0 / GABA-A Receptor Agonists; 0 / Indoles; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.4.3.4 / Monoamine Oxidase
  •  go-up   go-down


32. Sakata J, Wakai T, Shirai Y, Sakata E, Hasegawa G, Hatakeyama K: Humoral hypercalcemia complicating adenocarcinoma of the sigmoid colon: report of a case. Surg Today; 2005;35(8):692-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Humoral hypercalcemia complicating adenocarcinoma of the sigmoid colon: report of a case.
  • A 54-year-old woman was admitted with symptomatic hypercalcemia of 14.2 mg/dl and multiple hepatic metastases, 2 years after resection of sigmoid colon cancer.
  • The hypercalcemia was caused by the circulating parathyroid hormone-related peptide (PTHrP) produced by poorly differentiated adenocarcinoma in the liver.
  • [MeSH-major] Adenocarcinoma / complications. Hypercalcemia / etiology. Sigmoid Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1991 Nov-Dec;11(6):2029-30 [1776836.001]
  • [Cites] Lancet. 1993 Jun 26;341(8861):1611-3 [8099988.001]
  • [Cites] J Maine Med Assoc. 1969 Sep;60(9):205-7 [5351750.001]
  • [Cites] Dis Colon Rectum. 1985 Jun;28(6):440-5 [2988883.001]
  • [Cites] Am J Clin Oncol. 1995 Apr;18(2):126-9 [7900704.001]
  • [Cites] Cancer. 1969 Nov;24(5):1004-11 [4311108.001]
  • [Cites] N Engl J Med. 1963 Oct 10;269:801-8 [14053569.001]
  • [Cites] Am Surg. 2001 Jun;67(6):585-8 [11409809.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):2841-7 [8768840.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1111-6 [3300949.001]
  • [Cites] N Engl J Med. 1992 Apr 30;326(18):1196-203 [1532633.001]
  • [Cites] Am J Clin Oncol. 2002 Apr;25(2):160-3 [11943894.001]
  • [Cites] Dig Dis Sci. 1989 Jan;34(1):142-7 [2910674.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1265-8 [8918436.001]
  • [Cites] Med J Aust. 1994 Mar 7;160(5):286-7 [8107631.001]
  • [Cites] Oncol Rep. 1998 Jan-Feb;5(1):197-9 [9458321.001]
  • [Cites] Annu Rev Med. 1994;45:189-200 [8198376.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2217-21 [10590360.001]
  • (PMID = 16034553.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein
  • [Number-of-references] 19
  •  go-up   go-down


33. Kern RM, Yang Z, Kim PS, Grody WW, Iyer RK, Cederbaum SD: Arginase induction by sodium phenylbutyrate in mouse tissues and human cell lines. Mol Genet Metab; 2007 Jan;90(1):37-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyperargininemia is a urea cycle disorder caused by mutations in the gene for arginase I (AI) resulting in elevated blood arginine and ammonia levels.
  • The arginase specific activities for control and NaPB mice, respectively, were 38.2 and 59.4 U/mg in liver, 0.33 and 0.42 U/mg in kidney, and 0.29 and 1.19 U/mg in brain.
  • In some cell lines, NaPB increased arginase activity up to fivefold depending on dose (1-5 mM) and exposure time (2-5 days); control and NaPB activities, respectively, are: erythroleukemia, HEL, 0.06 and 0.31 U/mg, and K562, 0.46 and 1.74 U/mg; embryonic kidney, HEK293, 1.98 and 3.58 U/mg; breast adenocarcinoma, MDA-MB-468, 1.11 and 4.06 U/mg; and prostate adenocarcinoma, PC-3, 0.55 and 3.20 U/mg.
  • [MeSH-minor] Animals. Cell Line. Enzyme Induction / drug effects. Humans. Isoenzymes / biosynthesis. Liver / enzymology. Male. Mice. Mice, Inbred C57BL

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935537.001).
  • [ISSN] 1096-7192
  • [Journal-full-title] Molecular genetics and metabolism
  • [ISO-abbreviation] Mol. Genet. Metab.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD-0402411; United States / NICHD NIH HHS / HD / HD-06576; United States / NICHD NIH HHS / HD / HD-36415
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Phenylbutyrates; 7WY7YBI87E / 4-phenylbutyric acid; EC 3.5.3.1 / Arg2 protein, mouse; EC 3.5.3.1 / Arginase; EC 3.5.3.1 / arginase II, human
  •  go-up   go-down


34. Zen Y, Inoue D, Kitao A, Onodera M, Abo H, Miyayama S, Gabata T, Matsui O, Nakanuma Y: IgG4-related lung and pleural disease: a clinicopathologic study of 21 cases. Am J Surg Pathol; 2009 Dec;33(12):1886-93
MedlinePlus Health Information. consumer health - Pleural Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interestingly, 1 patient was found to have a primary adenocarcinoma against a background of IgG4-related lung disease during follow up.
  • It is important, therefore, to know the morphologic variety and clinicopathologic characteristics of this disorder.

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898222.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Immunoglobulin G; 0 / Steroids
  •  go-up   go-down


35. Su H, Shi DY, Li J, Guo SJ, Li LL, Yuan ZH, Zhu XB: Sesquiterpenes from Laurencia similis. Molecules; 2009;14(5):1889-97

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All these metabolites were submitted for a cytotoxicity assay against the tumor cell line BEL7402 (human liver adenocarcinoma), but all of them were found inactive (IC(50 )> 10 microg/mL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19471208.001).
  • [ISSN] 1420-3049
  • [Journal-full-title] Molecules (Basel, Switzerland)
  • [ISO-abbreviation] Molecules
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Sesquiterpenes
  •  go-up   go-down


36. An M, Shin JA, Lee SM, Yoon T, Park WS, Choi JI, Kim CM: [Liver metastasis of colon cancer with a high serum alpha-fetoprotein level: report of a case]. Korean J Hepatol; 2006 Dec;12(4):562-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver metastasis of colon cancer with a high serum alpha-fetoprotein level: report of a case].
  • We report herein a case of 72-year-old woman in whom liver metastasis of colon cancer was presented with a marked elevation of serum alpha-fetoprotein (AFP) level.
  • She was transferred to our hospital for multiple liver masses found on ultrasonogram.
  • Abdominal computed tomogram revealed multiple low-density masses in the liver and wall thickening of the hepatic flexure of colon.
  • Colonoscopic findings of ulcerofungating mass suggested liver metastasis from colon cancer.
  • Both colon and liver biopsies revealed moderately differentiated tubular adenocarcinoma.
  • Using an immunohistochemical staining, the adenocarcinoma in liver showed focal positive to AFP, but not in colon.
  • [MeSH-major] Colonic Neoplasms / pathology. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237635.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


37. Barshack I, Meiri E, Rosenwald S, Lebanony D, Bronfeld M, Aviel-Ronen S, Rosenblatt K, Polak-Charcon S, Leizerman I, Ezagouri M, Zepeniuk M, Shabes N, Cohen L, Tabak S, Cohen D, Bentwich Z, Rosenfeld N: Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression. Int J Biochem Cell Biol; 2010 Aug;42(8):1355-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression.
  • Distinguishing hepatocellular carcinoma from metastatic tumors in the liver is of great practical importance, with significant therapeutic and prognostic implications.
  • This differential diagnosis can be difficult because metastatic cancers in the liver, especially adenocarcinomas, may mimic the morphology and immunoexpression of hepatocellular carcinoma.
  • Biomarkers that are specifically expressed in either hepatocellular carcinoma or metastatic adenocarcinoma can therefore be useful diagnostic tools.
  • Hsa-miR-141 and hsa-miR-200c, microRNAs that promote epithelial phenotypes, had significantly higher levels in non-hepatic epithelial tumors.
  • Combinations of these microRNAs accurately identified primary hepatocellular carcinoma from metastatic adenocarcinoma in the liver.
  • Thus, the tissue-specific expression patterns of microRNAs make them useful biomarkers for the diagnosis of liver malignancies.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / genetics. Gene Expression Regulation, Neoplastic. Liver / metabolism. Liver Neoplasms / diagnosis. Liver Neoplasms / genetics. MicroRNAs / genetics
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Metastasis. ROC Curve. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20619223.001).
  • [ISSN] 1878-5875
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


38. Stern AW, Velguth KE, D'Agostino J: Metastatic ductal adenocarcinoma in a Western Hognose snake (Heterodon nasicus). J Zoo Wildl Med; 2010 Jun;41(2):320-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ductal adenocarcinoma in a Western Hognose snake (Heterodon nasicus).
  • Histologically, the mass was composed of tubules of columnar to flattened neoplastic cells with an abundant stroma and moderate cellular atypia consistent with a scirrhous adenocarcinoma, likely ductal in origin, given the location of the neoplastic mass.
  • Necropsy and histopathologic examination confirmed metastasis of the previously removed adenocarcinoma to the liver, right kidney, and large intestine.
  • [MeSH-major] Adenocarcinoma / veterinary. Snakes
  • [MeSH-minor] Animals. Female. Intestinal Neoplasms / secondary. Kidney Neoplasms / secondary. Liver Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20597225.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Donigan M, Loh BD, Norcross LS, Li S, Williamson PR, DeJesus S, Ferrara A, Gallagher JT, Baker CH: A metastatic colon cancer model using nonoperative transanal rectal injection. Surg Endosc; 2010 Mar;24(3):642-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two mice (3.3%) from the 2.5 x 10(4) CT26-luc group showed metastatic colonic adenocarcinoma to the liver on postinjection day 50.
  • [MeSH-major] Colonic Neoplasms / secondary. Neoplasm Transplantation / methods. Rectum / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Dig Surg. 2005;22(1-2):16-25 [15838167.001]
  • [Cites] Int J Cancer. 1989 Jul 15;44(1):177-81 [2744889.001]
  • [Cites] J Surg Res. 2009 Jun 15;154(2):299-303 [19101690.001]
  • [Cites] Cancer Res. 1975 Sep;35(9):2434-9 [1149045.001]
  • [Cites] Am J Pathol. 2007 Mar;170(3):1077-85 [17322390.001]
  • [Cites] Cancer Res. 1988 Apr 1;48(7):1943-8 [3349467.001]
  • [Cites] Arch Surg. 1995 Jun;130(6):649-53 [7763175.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):972-8 [12640542.001]
  • [Cites] Surg Endosc. 1998 Aug;12 (8):1092-5 [9685551.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Cancer Sci. 2004 Jun;95(6):514-9 [15182433.001]
  • [Cites] Eur J Surg Oncol. 2008 Apr;34(4):476-81 [17698312.001]
  • [Cites] Surg Oncol. 1992 Jun;1(3):251-6 [1341258.001]
  • [Cites] Int J Oncol. 2005 Jul;27(1):113-20 [15942650.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2556-61 [10873112.001]
  • (PMID = 19688392.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


40. Kok SH, Chui CH, Lam WS, Chen J, Lau FY, Wong RS, Cheng GY, Tang WK, Cheng CH, Tang JC, Chan AS: Mechanistic insight into a novel synthetic cantharidin analogue in a leukaemia model. Int J Mol Med; 2006 Aug;18(2):375-9
Hazardous Substances Data Bank. CANTHARIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously, we demonstrated that the novel synthetic cantharidin analogue CAN 032 possessed apoptotic activity on two human hepatoma cell lines Hep3B hepatocellular carcinoma and SK-Hep-1 liver adenocarcinoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820948.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CAN 032; 0 / Enzyme Inhibitors; 0 / Thiazoles; IGL471WQ8P / Cantharidin
  •  go-up   go-down


41. Dill AL, Ifa DR, Manicke NE, Ouyang Z, Cooks RG: Mass spectrometric imaging of lipids using desorption electrospray ionization. J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Sep 15;877(26):2883-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESI-MS has been used to image a variety of tissue samples including human liver adenocarcinoma, rat brain, human breast tissue and canine abdominal tumor tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Mass Spectrom. 2008 Apr;19(4):531-43 [18258448.001]
  • [Cites] Nat Protoc. 2008;3(3):517-24 [18323820.001]
  • [Cites] Anal Chem. 2008 Jun 15;80(12):4575-82 [18473485.001]
  • [Cites] Anal Chem. 2008 Jul 1;80(13):5168-77 [18481874.001]
  • [Cites] Science. 2008 Aug 8;321(5890):805 [18687956.001]
  • [Cites] Rapid Commun Mass Spectrom. 2008 Sep;22(17):2639-44 [18666197.001]
  • [Cites] Anal Chem. 2008 Nov 1;80(21):7921-9 [18844371.001]
  • [Cites] Anal Chem. 2008 Dec 1;80(23):8865-70 [19040400.001]
  • [Cites] Anal Chem. 2000 Feb 15;72(4):652-7 [10701247.001]
  • [Cites] Anal Chem. 2000 Nov 1;72(21):5239-43 [11080870.001]
  • [Cites] Nat Med. 2001 Apr;7(4):493-6 [11283679.001]
  • [Cites] J Mass Spectrom. 2001 Apr;36(4):355-69 [11333438.001]
  • [Cites] Free Radic Biol Med. 2002 Sep 1;33(5):620-6 [12208348.001]
  • [Cites] Indian J Exp Biol. 2002 Jun;40(6):656-67 [12587714.001]
  • [Cites] J Mass Spectrom. 2003 Jul;38(7):699-708 [12898649.001]
  • [Cites] Anal Chem. 2003 Jul 15;75(14):3429-34 [14570193.001]
  • [Cites] Anal Chem. 2004 Mar 15;76(6):1550-9 [15018551.001]
  • [Cites] Anal Chem. 2004 Mar 15;76(6):1657-63 [15018564.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4270-6 [15205341.001]
  • [Cites] Science. 2004 Jul 2;305(5680):71-3 [15232100.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):3930-4 [15253626.001]
  • [Cites] Anal Chem. 2004 Aug 1;76(15):4271-8 [15283560.001]
  • [Cites] J Card Fail. 2004 Aug;10(4):334-8 [15309701.001]
  • [Cites] J Am Soc Mass Spectrom. 2004 Oct;15(10):1499-508 [15465363.001]
  • [Cites] J Lipid Res. 1983 Apr;24(4):456-60 [6854152.001]
  • [Cites] J Lipid Res. 1984 Jul;25(7):738-49 [6481246.001]
  • [Cites] Lipids. 1987 Jul;22(7):480-9 [3626775.001]
  • [Cites] J Lipid Res. 1994 Jun;35(6):1102-14 [8077849.001]
  • [Cites] Anal Chem. 1994 Nov 15;66(22):3977-82 [7810900.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2028-34 [9329967.001]
  • [Cites] Anal Chem. 1997 Dec 1;69(23):4751-60 [9406525.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):80-4 [9892190.001]
  • [Cites] Anal Biochem. 1999 Feb 1;267(1):46-56 [9918654.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):279-86 [15591226.001]
  • [Cites] J Mass Spectrom. 2005 Aug;40(8):985-99 [16106340.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Nov 4;44(43):7094-7 [16259018.001]
  • [Cites] Analyst. 2005 Dec;130(12):1624-33 [16284661.001]
  • [Cites] J Chromatogr A. 2006 Mar 31;1110(1-2):86-94 [16480731.001]
  • [Cites] Chem Commun (Camb). 2006 Apr 28;(16):1709-11 [16609779.001]
  • [Cites] J Proteome Res. 2006 May;5(5):1107-16 [16674100.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(10):1577-84 [16628593.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(18):2717-27 [16912984.001]
  • [Cites] J Lipid Res. 2006 Oct;47(10):2101-11 [16902246.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(22):3403-8 [17051609.001]
  • [Cites] Angew Chem Int Ed Engl. 2006 Nov 6;45(43):7188-92 [17001721.001]
  • [Cites] Anal Bioanal Chem. 2007 Jan;387(2):539-49 [16821030.001]
  • [Cites] Anal Chem. 2007 Mar 15;79(6):2199-206 [17302385.001]
  • [Cites] Anal Chem. 2007 May 1;79(9):3514-8 [17394289.001]
  • [Cites] Analyst. 2007 May;132(5):461-7 [17471393.001]
  • [Cites] Anal Chem. 2007 Nov 1;79(21):8098-106 [17900146.001]
  • [Cites] Anal Chem. 2008 Apr 15;80(8):2780-8 [18314967.001]
  • (PMID = 19150258.001).
  • [ISSN] 1873-376X
  • [Journal-full-title] Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
  • [ISO-abbreviation] J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM058008-07; United States / NIGMS NIH HHS / GM / R01 GM058008; United States / NIGMS NIH HHS / GM / 5R01 GM58008-07; United States / NIGMS NIH HHS / GM / R01 GM058008-07
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Lipids
  • [Other-IDs] NLM/ NIHMS227068; NLM/ PMC2921711
  •  go-up   go-down


42. Rizell M, Lindner P: Inhibition of mTOR suppresses experimental liver tumours. Anticancer Res; 2005 Mar-Apr;25(2A):789-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of mTOR suppresses experimental liver tumours.
  • Sirolimus, and its antiproliferative capacity, was studied in vivo in three different syngenic rat tumours in the liver.
  • Treating established liver adenocarcinoma (n=15), sirolimus halved the tumour weight (1.4+/-0.2 g vs 0.7+/-0.1 g, p=0.005).
  • At this dose, there was no decrease in food consumption or rat weight, but decrease in weight of spleen, and increase in weight of liver (p<0.01).
  • The three tumours studied, an nitrosoguanidin-induced adenocarcinoma, a Leydig cell sarcoma and a hepatoma, all responded, establishing sirolimus as a promising anticancer drug.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Liver Neoplasms, Experimental / drug therapy. Liver Neoplasms, Experimental / enzymology. Protein Kinase Inhibitors / pharmacology. Protein Kinases / metabolism. Sirolimus / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Animals. Colonic Neoplasms / drug therapy. Colonic Neoplasms / enzymology. Dose-Response Relationship, Drug. Eating / drug effects. Leydig Cell Tumor / drug therapy. Leydig Cell Tumor / enzymology. Liver / anatomy & histology. Liver / metabolism. Organ Size / drug effects. Rats. Rats, Inbred WF. Spleen / anatomy & histology. TOR Serine-Threonine Kinases

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868910.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Protein Kinase Inhibitors; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, rat; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


43. Zhao SM, Zhu XZ, Ji Y, Hou J: [Expression of mucin glycoproteins and cytokeratins in intrahepatic cholangiocarcinoma]. Zhonghua Bing Li Xue Za Zhi; 2008 Nov;37(11):749-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To compare the immunoprofiles of intrahepatic cholangiocarcinoma and metastatic colorectal adenocarcinoma for mucin glycoproteins (including MUC1, MUC2, MUC5AC and MUC6) and cytokeratins (including CK7, CK19 and CK20), and to assess their diagnostic value.
  • METHODS: One hundred cases of intrahepatic cholangiocarcinoma and 21 cases of metastatic colorectal adenocarcinoma were enrolled into the study.
  • RESULTS: In intrahepatic cholangiocarcinoma, the expression rates of MUC1, MUC2, MUC5AC and MUC6 were 61.0%, 2.0%, 22.0% and 8.0% respectively, as compared to 57.1%, 47.6%, 19.0% and 23.8% respectively in metastatic colorectal adenocarcinoma.
  • On the other hand, the expression rates of CK7, CK19 and CK20 in intrahepatic cholangiocarcinoma were 73.0%, 53.0% and 15.0% respectively, in contrast to 14.3%, 90.5% and 85.7% respectively in metastatic colorectal adenocarcinoma.
  • CONCLUSIONS: The immunoprofile for mucin glycoproteins and cytokeratins provides important clues in distinguishing between intrahepatic cholangiocarcinoma and metastatic colorectal adenocarcinoma to liver.
  • The immunophenotype of MUC2-/MUC6-/CK7+/CK20- indicates the diagnosis of intrahepatic cholangiocarcinoma, while MUC2+/MUC6+/CK7-/CK20+ suggests the possibility of metastatic colorectal adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Female. Glycoproteins / metabolism. Humans. Male. Middle Aged. Neoplasm Staging / classification

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094709.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Mucins; 68238-35-7 / Keratins
  •  go-up   go-down


44. Chansri N, Kawakami S, Yamashita F, Hashida M: Inhibition of liver metastasis by all-trans retinoic acid incorporated into O/W emulsions in mice. Int J Pharm; 2006 Sep 14;321(1-2):42-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of liver metastasis by all-trans retinoic acid incorporated into O/W emulsions in mice.
  • All-trans retinoic acid (ATRA) was incorporated into lipid emulsions in an attempt to alter its distribution characteristics and improve its inhibition of liver cancer metastasis.
  • After intravenous administration in mice, [3H]cholesteryl hexadecyl ether incorporated into emulsion, which is the inherent distribution of emulsions, accumulated gradually mainly in the liver.
  • The blood concentration and hepatic accumulation of [3H]ATRA incorporated into emulsion was significantly higher than that of serum dissolving [3H]ATRA, which represent the original distribution characteristic of free ATRA.
  • In a murine liver metastasis model by colon adenocarcinoma, the liver metastasis number and liver weight were significantly reduced and the survival time of mice was prolonged following intravenous injection of ATRA incorporated into emulsions.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Liver Neoplasms, Experimental / prevention & control. Liver Neoplasms, Experimental / secondary. Tretinoin / administration & dosage

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16790329.001).
  • [ISSN] 0378-5173
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Emulsions; 5688UTC01R / Tretinoin; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


45. Yamasaki T, Nebiki H, Sasaki E, Kurai O: Successful treatment of duodenal adenocarcinoma with multiple liver metastases by S-1 + irinotecan (CPT-11). Clin J Gastroenterol; 2009 Aug;2(4):287-290

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of duodenal adenocarcinoma with multiple liver metastases by S-1 + irinotecan (CPT-11).
  • Unresectable duodenal adenocarcinoma excluding the ampullary region is rare, and no standard chemotherapy has been defined for this disease.
  • We present herein a case of duodenal adenocarcinoma with liver metastases.
  • Gastroduodenal endoscopy revealed an ulcerative lesion on the upper wall of the duodenal bulb, and biopsy specimens showed well-differentiated adenocarcinoma.
  • Computed tomography and ultrasonography showed multiple liver metastases.
  • Tumor markers subsequently normalized, and liver metastases were diminished.
  • The patient died due to hepatic failure, with an overall survival of 15 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998 Aug;78(4):508-10 [9716035.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Mar;19(2):143-9 [17355111.001]
  • [Cites] J Chemother. 2006 Oct;18(5):545-8 [17127233.001]
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2602-6 [8653704.001]
  • [Cites] J Chemother. 2003 Oct;15(5):503-6 [14598944.001]
  • [Cites] Oncology. 1999 Oct;57(3):202-10 [10545788.001]
  • [Cites] Oncologist. 2005 Feb;10(2):132-7 [15709215.001]
  • [Cites] Oncology. 2007;73(1-2):65-71 [18334851.001]
  • [Cites] Cancer. 1977 Apr;39(4):1721-6 [322840.001]
  • [Cites] Arch Surg. 1974 Jun;108(6):805-7 [4545398.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Ann Surg. 1979 Aug;190(2):179-82 [464691.001]
  • [Cites] Dig Dis Sci. 2007 Apr;52(4):1121-4 [17226074.001]
  • (PMID = 26192427.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Chemotherapy / Duodenal cancer / Irinotecan / Liver metastases / S-1
  •  go-up   go-down


46. Wernicke J, Pangallo B, Wang F, Murray I, Henck JW, Knadler MP, D'Souza DN, Uetrecht JP: Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Curr Drug Saf; 2008 May;3(2):132-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic effects of duloxetine-I: non-clinical and clinical trial data.
  • OBJECTIVE: Review nonclinical and clinical trial data for hepatic effects of duloxetine.
  • Hepatic-related treatment-emergent adverse events were uncommon.
  • Seven of 23,000 duloxetine- and 2/6000 placebo-treated patients met criteria for modified Hy's rule (significant elevation of both ALT and total bilirubin) but were complicated by contributing factors such as excessive alcohol consumption (n=3), gall stones, common bile duct calculus, hepatitis C, and liver adenocarcinoma (n=1 each).
  • CONCLUSIONS: Duloxetine has an effect on the liver, manifested by transient, self-limiting transaminase elevations.
  • Rare events characterized as hepatocellular injury, cholestatic injury, or mixed type of hepatic injury have been reported.
  • The pattern of liver effects was different from that in laboratory animals.
  • [MeSH-major] Adrenergic Uptake Inhibitors / adverse effects. Drug-Induced Liver Injury. Liver / drug effects. Serotonin Uptake Inhibitors / adverse effects. Thiophenes / adverse effects
  • [MeSH-minor] Alanine Transaminase / blood. Alkaline Phosphatase / blood. Animals. Aspartate Aminotransferases / blood. Bilirubin / blood. Biomarkers / blood. Clinical Trials as Topic. Consumer Product Safety. Drug Evaluation, Preclinical. Duloxetine Hydrochloride. Humans. Liver Diseases / enzymology. Risk Assessment. Risk Factors. Species Specificity

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. DULOXETINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Curr Drug Saf. 2009 Jan;4(1):94
  • (PMID = 18690991.001).
  • [ISSN] 2212-3911
  • [Journal-full-title] Current drug safety
  • [ISO-abbreviation] Curr Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Adrenergic Uptake Inhibitors; 0 / Biomarkers; 0 / Serotonin Uptake Inhibitors; 0 / Thiophenes; 9044SC542W / Duloxetine Hydrochloride; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 3.1.3.1 / Alkaline Phosphatase; RFM9X3LJ49 / Bilirubin
  • [Number-of-references] 30
  •  go-up   go-down


47. Hornick JL, Lauwers GY, Odze RD: Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol; 2005 Mar;29(3):381-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
  • Not uncommonly, bile duct adenomas (BDAs) and hamartomas (BDHs) of the liver may be difficult to distinguish from metastatic well-differentiated ductal adenocarcinoma of the pancreas.
  • The primary purpose of this study was to determine if a panel of immunohistochemical stains can help distinguish BDA or BDH from metastatic pancreatic adenocarcinoma in the liver.
  • Routinely processed tissue sections from 25 BDA, 10 BDH, 25 metastatic pancreatic adenocarcinomas to the liver and 6 cases each of metastatic colorectal, breast, and lung adenocarcinomas were immunohistochemically stained for CK7, CK8/CK18, CK19, CK20, p53, p63, TAG-72, monoclonal CEA (mCEA), polyclonal CEA (pCEA), HER-2/neu, AMACR (alpha-methylacyl-CoA racemase), Dpc4 (Smad4), and mesothelin.
  • The slides were evaluated in a blinded fashion, and the results were compared between the benign and malignant lesions.
  • Of these antibodies, p53, TAG-72, mCEA, loss of Dpc4, and mesothelin had the highest specificity for pancreatic adenocarcinoma, with mCEA having the highest sensitivity (92%).
  • For nonpancreatic adenocarcinomas, mCEA showed a reasonably high sensitivity and 100% specificity in the differential diagnosis versus BDA.
  • Immunohistochemical expression of p53, TAG-72, mCEA, mesothelin, and loss of Dpc4 can help distinguish metastatic pancreatic adenocarcinoma in the liver from BDA or BDH.
  • Although p63 and AMACR are also specific for pancreatic adenocarcinoma, their low sensitivity limits their use in clinical practice.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma / pathology. Bile Duct Neoplasms / pathology. Hamartoma / pathology. Liver Diseases / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Immunoenzyme Techniques


48. Burgess LC, Rice E, Fischer T, Seekins JR, Burgess TP, Sticka SJ, Klatt K: Lycopene has limited effect on cell proliferation in only two of seven human cell lines (both cancerous and noncancerous) in an in vitro system with doses across the physiological range. Toxicol In Vitro; 2008 Aug;22(5):1297-300
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Hep-G2, liver adenocarcinoma cell line, showed a reduction at the high doses after 24 h and the IMR-90, noncancerous lung cell line, showed a reduction at the highest dose after 72 h when compared to the solvent control.
  • The A431, skin carcinoma, DU-145, prostate carcinoma, HS-68, noncancerous skin, A549, lung carcinoma, and HS-578T, breast carcinoma, all showed no reduction in proliferation.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 1998 Sep 29;250(3):582-5 [9784387.001]
  • [Cites] Nutr Cancer. 1995;24(3):257-66 [8610045.001]
  • [Cites] J Nutr. 2004 Dec;134(12 Suppl):3486S-3492S [15570058.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):1010-4 [15514967.001]
  • [Cites] J Nutr. 2005 Feb;135(2):287-90 [15671228.001]
  • [Cites] Exp Biol Med (Maywood). 2005 Mar;230(3):171-9 [15734720.001]
  • [Cites] Biofactors. 2005;23(3):129-39 [16410635.001]
  • [Cites] Oncol Nurs Forum. 2006 Jan;33(1):127-37 [16470241.001]
  • [Cites] J Nutr. 2006 May;136(5):1287-93 [16614418.001]
  • [Cites] Toxicol In Vitro. 2007 Mar;21(2):217-23 [17140762.001]
  • [Cites] Biomed Pharmacother. 2007 Jul;61(6):366-9 [17448625.001]
  • [Cites] Arch Biochem Biophys. 1996 Dec 1;336(1):1-9 [8951028.001]
  • [Cites] J Nutr. 2001 May;131(5):1574-80 [11340118.001]
  • [Cites] Life Sci. 2001 Nov 2;69(24):2819-31 [11720086.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):391-8 [11880478.001]
  • [Cites] J Nutr. 2002 Mar;132(3):404-8 [11880563.001]
  • [Cites] J Agric Food Chem. 2002 Apr 10;50(8):2214-9 [11929273.001]
  • [Cites] J Nutr. 2002 Dec;132(12):3754-9 [12468619.001]
  • [Cites] J Med Food. 2002 Winter;5(4):181-7 [12639392.001]
  • [Cites] J Lipid Res. 2003 Oct;44(10):1927-39 [12867539.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(11):1768-75 [15251168.001]
  • [Cites] Arch Biochem Biophys. 2004 Oct 1;430(1):127-34 [15325920.001]
  • [Cites] Am J Health Syst Pharm. 2004 Aug 1;61(15):1562-6 [15372829.001]
  • [Cites] Int J Cancer. 2004 Nov 20;112(4):689-92 [15382052.001]
  • [Cites] J Med Food. 2004 Fall;7(3):284-9 [15383220.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1225-30 [10096552.001]
  • (PMID = 18434082.001).
  • [ISSN] 0887-2333
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016471; United States / NCRR NIH HHS / RR / RR016471-07; United States / NCRR NIH HHS / RR / P20 RR016471-07; United States / NCRR NIH HHS / RR / P20 RR016741
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 36-88-4 / Carotenoids; SB0N2N0WV6 / lycopene
  • [Other-IDs] NLM/ NIHMS57454; NLM/ PMC2494863
  •  go-up   go-down


49. Godoy A, Ulloa V, Rodríguez F, Reinicke K, Yañez AJ, García Mde L, Medina RA, Carrasco M, Barberis S, Castro T, Martínez F, Koch X, Vera JC, Poblete MT, Figueroa CD, Peruzzo B, Pérez F, Nualart F: Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol; 2006 Jun;207(3):614-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, a previous immunohistochemical analysis of GLUT1 expression in 154 malignant human neoplasms failed to detect the GLUT1 isoform in 87 tumors.
  • GLUT6 was principally detected in testis germinal cells and GLUT9 was localized in kidney, liver, heart, and adrenal.
  • GLUT2 was detected in 31% of the samples, being mainly expressed in breast, colon, and liver carcinoma.
  • GLUT5 was detected in 27% of breast and colon adenocarcinoma, liver carcinoma, lymphomas, and testis seminoma samples.
  • The extensive expression of GLUT2 and 5 (glucose/fructose and fructose transporters, respectively) in malignant human tissues indicates that fructose may be a good energy substrate in tumor cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16523487.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transport Proteins, Facilitative
  •  go-up   go-down


50. Kok SH, Chui CH, Lam WS, Chen J, Lau FY, Cheng GY, Wong RS, Lai PP, Leung TW, Tang JC, Chan AS: Apoptotic activity of a novel synthetic cantharidin analogue on hepatoma cell lines. Int J Mol Med; 2006 May;17(5):945-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although both showed an apoptotic induction ability on cancer cells, they were still relatively toxic towards non-malignant haematological disordered bone marrow.
  • The cytotoxic activity of this analogue was screened on both Hep3B hepatocellular carcinoma and SK-Hep-1 liver adenocarcinoma cell lines by [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) assay.
  • The possible tolerance of these analogues was further investigated using non-malignant haematological bone marrow primary culture.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CANTHARIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596285.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CAN 032; 0 / Thiazoles; IGL471WQ8P / Cantharidin
  •  go-up   go-down


51. Chui CH, Gambari R, Lau FY, Cheng GY, Wong RS, Kok SH, Tang JC, Teo IT, Cheung F, Cheng CH, Ho KP, Chan AS, Wong A: In vitro anti-cancer activity of a novel microbial fermentation product on human carcinomas. Int J Mol Med; 2006 Apr;17(4):675-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The possible anti-proliferation and cell death induction potential of a novel microbial fermentation extract named as oncogen XP-180 (or simply as XP-180) was tested on three human solid tumour carcinoma cell lines (non-small cell lung cancer A549, breast cancer MDA-MB231, liver adenocarcinoma SK-Hep1) and on the acute myelogenous leukaemia KG1a cell line.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525727.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Antineoplastic Agents; 0 / Biological Products; 0 / Caspase Inhibitors; 0 / Cysteine Proteinase Inhibitors; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / CASP9 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9; EC 3.4.22.- / Caspases
  •  go-up   go-down


52. Darby IA, Vuillier-Devillers K, Pinault E, Sarrazy V, Lepreux S, Balabaud C, Bioulac-Sage P, Desmoulière A: Proteomic analysis of differentially expressed proteins in peripheral cholangiocarcinoma. Cancer Microenviron; 2010;4(1):73-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cholangiocarcinoma is an adenocarcinoma of the liver which has increased in incidence over the last thirty years to reach similar levels to other liver cancers.
  • Diagnosis of this disease is usually late and prognosis is poor, therefore it is of great importance to identify novel candidate markers and potential early indicators of this disease as well as molecules that may be potential therapeutic targets.
  • We have used a proteomic approach to identify differentially expressed proteins in peripheral cholangiocarcinoma cases and compared expression with paired non-tumoral liver tissue from the same patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2004 Apr 22;23(19):3495-500 [14990989.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):329-39 [15093540.001]
  • [Cites] Proteomics. 2005 May;5(7):1914-27 [15816005.001]
  • [Cites] Proteomics. 2006 Feb;6(3):1049-57 [16400691.001]
  • [Cites] Proteomics. 2006 Jun;6(11):3466-76 [16645984.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Nov;132(11):685-97 [16786358.001]
  • [Cites] Antioxid Redox Signal. 2006 Jul-Aug;8(7-8):1263-72 [16910774.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1546-54 [16980951.001]
  • [Cites] Oncogene. 2007 Mar 29;26(14):2082-94 [17043657.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1396-403 [17060937.001]
  • [Cites] Br J Cancer. 2007 Feb 12;96(3):477-84 [17245342.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2082-90 [17404090.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3185-91 [17409426.001]
  • [Cites] Biochim Biophys Acta. 2007 Jul;1772(7):766-72 [17490866.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):332-8 [17621266.001]
  • [Cites] Histochem Cell Biol. 2007 Sep;128(3):217-26 [17661067.001]
  • [Cites] Cancer Res. 2007 Aug 15;67(16):7901-6 [17699796.001]
  • [Cites] Proteomics. 2004 Mar;4(3):793-811 [14997500.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3992-4003 [15082792.001]
  • [Cites] Mol Cancer. 2007;6:80 [18086302.001]
  • [Cites] J Proteome Res. 2008 Feb;7(2):611-20 [18161940.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):162-7 [18162532.001]
  • [Cites] World J Gastroenterol. 2008 Feb 7;14(5):666-74 [18205254.001]
  • [Cites] Oncogene. 2008 Jun 5;27(25):3624-34 [18223688.001]
  • [Cites] Lancet Oncol. 2008 Feb;9(2):149-58 [18237849.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):221-8 [18271918.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Mar;23 Suppl 1:S73-7 [18336669.001]
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2707-18 [18381746.001]
  • [Cites] Mol Nutr Food Res. 2008 Nov;52(11):1289-99 [18435490.001]
  • [Cites] J Clin Lab Anal. 2008;22(3):204-9 [18484658.001]
  • [Cites] Mol Cancer. 2010;9:13 [20096135.001]
  • [Cites] FEBS Lett. 2010 Apr 16;584(8):1443-8 [20206173.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6291-4 [2169343.001]
  • [Cites] Electrophoresis. 1988 Jun;9(6):255-62 [2466658.001]
  • [Cites] Int J Cancer. 1998 Jun 19;79(3):232-40 [9645343.001]
  • [Cites] J Hepatol. 1996 Jun;24(6):706-12 [8835746.001]
  • [Cites] Histochem Cell Biol. 2003 Oct;120(4):265-75 [14574581.001]
  • [Cites] Clin Exp Metastasis. 2004;21(6):485-94 [15679046.001]
  • [Cites] Arch Pathol Lab Med. 2005 Jun;129(6):790-3 [15913431.001]
  • [Cites] Pathol Int. 2005 Nov;55(11):724-31 [16271085.001]
  • [Cites] Mol Carcinog. 2006 May;45(5):279-87 [16550611.001]
  • [Cites] Int J Biol Markers. 2006 Jan-Mar;21(1):40-4 [16711512.001]
  • [Cites] Pediatr Res. 2006 Aug;60(2):233-8 [16864711.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):95-102 [16890323.001]
  • [Cites] Amino Acids. 2008 Feb;34(2):195-202 [17031478.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 May;5(5):624-9 [17478349.001]
  • [Cites] BMC Cancer. 2007;7:169 [17764575.001]
  • [Cites] Int J Oncol. 2007 Dec;31(6):1301-8 [17982655.001]
  • [Cites] Cancer Sci. 2008 Mar;99(3):497-501 [18081878.001]
  • [Cites] J Cell Biochem. 2008 Aug 15;104(6):2165-73 [18452139.001]
  • [Cites] Proc Chin Acad Med Sci Peking Union Med Coll. 1990;5(1):13-8 [2371260.001]
  • [Cites] J Cell Sci. 1986 Jun;82:309-20 [3793784.001]
  • [Cites] Mol Cell. 2000 Jul;6(1):41-51 [10949026.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):555-60 [10228861.001]
  • [Cites] Hum Pathol. 1996 Jun;27(6):599-604 [8666372.001]
  • [Cites] Anticancer Res. 2000 Jul-Aug;20(4):2489-94 [10953316.001]
  • [Cites] J Hepatol. 2000 Dec;33(6):907-14 [11131452.001]
  • [Cites] Mol Pharmacol. 2001 Dec;60(6):1325-31 [11723239.001]
  • [Cites] Cell Growth Differ. 2002 May;13(5):227-36 [12065246.001]
  • [Cites] Breast Cancer Res Treat. 2003 Feb;77(3):245-52 [12602924.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4765-73 [12879023.001]
  • [Cites] FEBS Lett. 1992 Nov 2;312(1):47-52 [1385211.001]
  • [Cites] World J Gastroenterol. 2004 Feb 15;10(4):509-13 [14966907.001]
  • (PMID = 21505563.001).
  • [ISSN] 1875-2284
  • [Journal-full-title] Cancer microenvironment : official journal of the International Cancer Microenvironment Society
  • [ISO-abbreviation] Cancer Microenviron
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC3047624
  • [Keywords] NOTNLM ; Cholangiocarcinoma / Myofibroblast / Periostin / Tumor stroma / α-smooth muscle actin
  •  go-up   go-down


53. Gao J, Kashfi K, Liu X, Rigas B: NO-donating aspirin induces phase II enzymes in vitro and in vivo. Carcinogenesis; 2006 Apr;27(4):803-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the effect of NO-ASA on drug metabolizing enzymes in HT-29 human colon adenocarcinoma and Hepa 1c1c7 mouse liver adenocarcinoma cells and in Min mice treated with NO-ASA for 3 weeks.
  • Compared with untreated Min mice, NO-ASA increased in the liver the activity (nmol/min/mg; mean+/-SEM for all) of NQO (85+/-6 versus 128+/-11, P<0.05) and GST (2560+/-233 versus 4254+/-608, P<0.005) and also in the intestine but not in the kidney; the expression of NQO1 and GST P1-1 was also increased.
  • [MeSH-major] Adenocarcinoma / prevention & control. Aspirin / analogs & derivatives. Colonic Neoplasms / prevention & control. Glutathione Transferase / metabolism. Liver Neoplasms / prevention & control. NAD(P)H Dehydrogenase (Quinone) / metabolism. Nitric Oxide / pharmacology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16267095.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA92423
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / KEAP1 protein, human; 0 / NF-E2-Related Factor 2; 0 / NFE2L2 protein, human; 0 / Proteins; 175033-36-0 / nitroaspirin; 31C4KY9ESH / Nitric Oxide; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 2.5.1.18 / Glutathione Transferase; R16CO5Y76E / Aspirin
  •  go-up   go-down


54. Chiu CT, Chiang JM, Yeh TS, Tseng JH, Chen TC, Jan YY, Chen MF: Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges? Dig Liver Dis; 2008 Sep;40(9):749-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges?
  • BACKGROUNDS/AIMS: Intrahepatic cholangiocarcinoma and colorectal cancer liver metastasis are the most primary and secondary adenocarcinoma of the liver, respectively.
  • METHODS: A total of 166 colorectal cancer liver metastasis patients and 206 intrahepatic cholangiocarcinoma patients who had undergone curative liver resection were retrospectively analysed.
  • RESULTS: The intrahepatic cholangiocarcinoma patients were more female-predominated, associated with hepatolithiasis, symptomatic, jaundiced, and with larger tumour size compared with those of colorectal cancer liver metastasis.
  • Prognostic factors of intrahepatic cholangiocarcinoma were pathologic staging, histologic pattern and section margin; whereas prognostic factors of colorectal cancer liver metastasis were rectal origin, differentiation, section margin and bilobar distribution.
  • CK7 and CK20 differentiated majority of intrahepatic cholangiocarcinoma from colorectal cancer liver metastasis, while CDX2 and MUC5AC helped to differentiate inconclusive cases.
  • The 1-, 3-, 5- and 10-year survival rates of colorectal cancer liver metastasis were 77%, 31%, 20% and 14%, compared to 53%, 21%, 13% and 7% of intrahepatic cholangiocarcinoma (p=.0001).
  • Furthermore, the survival of colorectal cancer liver metastasis was comparable to staged II intrahepatic cholangiocarcinoma (p=.8866) and intraductal growth type-intrahepatic cholangiocarcinoma (p=.1915).
  • CONCLUSIONS: Demographics, precipitating factor, clinical manifestations, and prognostic factors of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma differed remarkably.
  • High incidence of CDX2 and MUC2 expression in colorectal cancer liver metastasis and intraductal growth type-intrahepatic cholangiocarcinoma might explain their similar cytoarchitecture and survival.
  • [MeSH-major] Adenocarcinoma / secondary. Bile Duct Neoplasms / pathology. Biomarkers, Tumor / analysis. Cholangiocarcinoma / pathology. Colorectal Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Bile Ducts, Intrahepatic. Biopsy, Needle. Cohort Studies. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Probability. Prognosis. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis


55. Gómez-Raposo C, Nistal M, De Castro Carpeño J, Sosa Rotundo G, Belda-Iniesta C, Casado E, González Barón M: Retroperitoneal Castleman's disease with colon cancer. A rare association. Clin Transl Oncol; 2008 Apr;10(4):238-40
Genetic Alliance. consumer health - Castleman's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Castleman's disease (CD) is a rare disorder of uncertain aetiology characterised by massive proliferation of lymphoid tissue usually localised as mediastinal masses, although abdominal involvement has been reported.
  • A patient with plasma cell subtype unicentric CD localised in retroperitoneum associated with an adenocarcinoma of ileocaecal valve and liver metastasis is reported.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1202-16 [4031967.001]
  • [Cites] Am J Hematol. 2002 Feb;69(2):119-26 [11835348.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):471-7 [12580962.001]
  • [Cites] N Engl J Med. 1995 Sep 21;333(12):798; author reply 798-9 [7643891.001]
  • [Cites] Indian J Pathol Microbiol. 2002 Jul;45(3):335-6 [12785179.001]
  • [Cites] Cancer. 1972 Mar;29(3):670-83 [4551306.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):706-17 [10091744.001]
  • [Cites] Hinyokika Kiyo. 1992 Sep;38(9):1041-4 [1414756.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):670-6 [11505414.001]
  • (PMID = 18411199.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


56. Katakura Y, Suzuki M, Kobayashi M, Nakahara K, Matsumoto N, Itoh F: Remission of primary duodenal adenocarcinoma with liver metastases with S-1 chemotherapy. Dig Dis Sci; 2007 Apr;52(4):1121-4
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of primary duodenal adenocarcinoma with liver metastases with S-1 chemotherapy.
  • [MeSH-minor] Adenocarcinoma. Aged. Drug Combinations. Female. Humans. Liver Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1994 Oct;81(10):1472-4 [7820475.001]
  • [Cites] Am J Clin Oncol. 1996 Jun;19(3):305-6 [8638547.001]
  • [Cites] Dig Surg. 2004;21(5-6):434-8; discussion 438-9 [15665538.001]
  • [Cites] Am J Surg. 1981 Feb;141(2):228-31 [6257130.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):141-5 [10901361.001]
  • [Cites] Hepatogastroenterology. 1997 Jul-Aug;44(16):1157-63 [9261617.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2355-61 [15160338.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Ann Surg Oncol. 1994 Jan;1(1):73-8 [7834432.001]
  • [Cites] Cancer. 1977 Apr;39(4):1721-6 [322840.001]
  • [Cites] Panminerva Med. 1997 Mar;39(1):24-9 [9175417.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Dig Dis Sci. 1991 Nov;36(11):1653-6 [1935506.001]
  • [Cites] J Gastrointest Surg. 1998 Jan-Feb;2(1):79-87 [9841972.001]
  • [Cites] Am Surg. 1998 Dec;64(12):1165-9 [9843337.001]
  • (PMID = 17226074.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down






Advertisement